We conducted a systematic review and network meta-analysis for the risk of DKA associated with SGLT2 inhibitors in the adjuvant treatment of T1DM, with the aim of providing some reference for the safety convenience of clinical use of SGLT2 inhibitors in the adjuvant treatment of T1DM. Here, SLC5A2 is linked to type 1 diabetes mellitus.